9 Meters Biopharma
NMTR
NMTR was delisted on the 25th of July, 2023.
19 hedge funds and large institutions have $2.81M invested in 9 Meters Biopharma in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 13 closing their positions.
31% less capital invested
Capital invested by funds: $4.07M → $2.81M (-$1.26M)
37% less funds holding
Funds holding: 30 → 19 (-11)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
70% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 10
77% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SXL
Summit X LLC
Chesterfield,
Missouri
|
+$19.2K |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$4.18K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$404 |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$364 |
| 5 |
CG
Cutler Group
San Francisco,
California
|
+$101 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$227K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$168K |
| 3 |
Millennium Management
New York
|
-$111K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$104K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$88.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| – | -$3K | -130 | Closed |
|
|
MAM
27
Meeder Asset Management
Dublin,
Ohio
| – | -$2K | -75 | Closed |
|
28
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$1K | -63 | Closed |
|
29
Barclays
London,
United Kingdom
| – | -$242 | -12 | Closed |
|
|
IA
30
IFP Advisors
Tampa,
Florida
| – | +$20 | +1 | New |
|
|
31
Simplex Trading
Chicago,
Illinois
| – | +$404 | +20 | +118% |
|
NMTR Hedge Fund Activity: Q3 2019 in Review
19 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q3 2019, worth a combined $2.81M — down 31% from $4.07M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of NMTR and 3 opened new positions — a net loss of 10 holders — while 10 trimmed existing stakes and 3 added.
The largest buyer was Summit X LLC, opening a new position worth an estimated $19.2K. The largest seller was Vanguard Group, cutting an estimated $227K.
- 19 institutional investors held 9 Meters Biopharma (NMTR) as of Q3 2019, down from 30 in Q2 2019.
- Funds reported $2.81M of 9 Meters Biopharma stock for Q3 2019, down 31% quarter-over-quarter.
- 3 funds opened new 9 Meters Biopharma positions in Q3 2019 and 13 closed out, a net change of -10 holders.
- The largest 9 Meters Biopharma buyer in Q3 2019 was Summit X LLC, an estimated $19.2K added.
- The largest 9 Meters Biopharma seller in Q3 2019 was Vanguard Group, an estimated $227K sold.
Based on aggregated 13F filings for Q3 2019.